PTC Therapeutics won a bankruptcy auction bid of $211 million for a Sangamo gene therapy program targeting Fabry disease. The deal centers on ST-920, a one-time AAV gene therapy that is described as BLA-ready, as Sangamo works through Chapter 11 proceedings after failing to find strategic alternatives. The transaction structure described analysts as a higher-risk, higher-reward bet given the regulatory pathway ahead for the therapy. PTC is set to provide Sangamo $111 million upfront, with additional contingent milestones potentially reaching $100 million based on regulatory approvals. As Sangamo’s assets rotate through bankruptcy channels, PTC’s selection highlights how near-regulatory gene therapy developers can attract capital quickly when clinical and CMC readiness align. For Fabry, the auction outcome potentially increases the odds of a faster path to market compared with waiting for a reoriented development strategy from the distressed original owner.